<DOC>
	<DOCNO>NCT00633295</DOCNO>
	<brief_summary>The mainstay therapy GISTs surgical resection , however , recurrence almost inevitable high-risk tumor secondary surgery salvage therapy yield poor outcome . The median survival patient unresectable metastatic GIST approximately 20 month , patient local recurrence 9 12 month . Responses chemotherapy best 5 % . The introduction imatinib dramatically change prognosis patient yield response rate 41 % 71 % overall clinical benefit ( tumor response plus stable disease ) range 73 % 90 % . However , resistance imatinib may develop represent clinical challenge . Sunitinib recently approve FDA patient whose disease progress intolerant imatinib therapy . Patients tumor progress sunitinib another 2nd line agent limit therapeutic alternative . Reinstitution imatinib , possible , consider acceptable option patient may slow rate disease progression even set prior imatinib failure ; however optimal 3rd line treatment need . AMN107 novel aminopyrimidine , available oral formulation ATP -competitive inhibitor BCR-ABL , potent Imatinib . It inhibit proliferation autophosphorylation 32 33 BCR-ABL point mutation . In addition AMN107 also inhibit PDGFRα , PDGFRβ , KIT . Preliminary data ongoing Phase I study imatinib-resistant GIST patient ( CAMN107A2103 ) indicate AMN107 alone ( 400 mg BID ) combination imatinib ( imatinib 400 mg BID plus AMN107 200 mg QD 400 mg QD ) well tolerate pre-treated patient .</brief_summary>
	<brief_title>Phase II Study Aiming Evaluate Efficacy Safety Nilotinib Patients With Gastrointestinal Stromal Tumors ( GIST ) Resistant Intolerant Imatinib 2nd Line Tyrosine Kinas ( TK ) Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Inclusion criterion : Age ≥ 18 year Visit 1 Radiological confirmation disease progression ( CT scan PETCT , MRI ) imatinib therapy , 600 800 mg per day least 6 week . Radiological confirmation disease progression ( CT scan MRI PETCT ) 2nd line TK inhibitor therapy . Patients intolerant Imatinib second line TK inhibitor ( like : sunitinib ) . Intolerance ( dose and/or duration ) , define patient progress imatinib sunitinib discontinue imatinib sunitinib therapy due ≥ Grade 3 adverse event persist spite optimal supportive care . Patients Grade 2 adverse event related imatinib sunitinib therapy , spite optimal supportive care measure , persist ≥ one month recur 3 time whether dose reduce discontinue also qualify patient intolerant Exclusion criterion : Prior treatment nilotinib Treatment investigational drug ≤ 4 week prior Visit 1 exception imatinib sunitinib therapy . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>GIST</keyword>
	<keyword>TKI</keyword>
	<keyword>IMATINIB</keyword>
	<keyword>NILOTINIB</keyword>
	<keyword>AMN107</keyword>
</DOC>